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Abstract: Cancer heterogeneity and progression are subject to complex interactions between neoplastic
cells and their microenvironment, including the immune system. Although glioblastomas (GBMs)
are classified as ‘cold tumours’ with very little lymphocyte infiltration, they can contain up to
30–40% of tumour-associated macrophages, reported to contribute to a supportive microenvironment
that facilitates tumour proliferation, survival and migration. In GBM, tumour-associated
macrophages comprise either resident parenchymal microglia, perivascular macrophages or peripheral
monocyte-derived cells. They are recruited by GBMs and in turn release growth factors and cytokines
that affect the tumour. Notably, tumour-associated microglia/macrophages (TAMs) acquire different
expression programs, which shape the tumour microenvironment and contribute to GBM molecular
subtyping. Further, emerging evidence highlights that TAM programs may adapt to specific tumour
features and landscapes. Here, we review key evidence describing TAM transcriptional and functional
heterogeneity in GBM. We propose that unravelling the intricate complexity and diversity of the
myeloid compartment as well as understanding how different TAM subsets may affect tumour
progression will possibly pave the way to new immune therapeutic avenues for GBM patients.
Keywords: glioblastoma; tumour-associated microglia/macrophages; cellular heterogeneity;
immunotherapy; precision medicine
1. Introduction
Gliomas represent approximately 80% of all malignant tumours of the central nervous system
(CNS) [1]. Among them, glioblastoma (GBM) is the highest-grade glioma (grade IV) and the most
common malignant brain tumour in adults. The standard care of treatment for GBM relies on maximal
surgical resection followed by radiation therapy and concomitant chemotherapy with the alkylating
agent temozolomide as established in 2005 [2]. However, recurrence is inevitable, and prognosis
remains poor with a median survival of 15 months after diagnosis. Hence, the development of novel
therapeutic options, including immunotherapies, are needed.
The immune landscape of brain tumours is intensely investigated, unveiling new insight in the
interactions between neoplastic cells and the immune system [3]. GBM is a highly immunosuppressive
cancer, where resident microglia and peripheral infiltrated macrophages play a key role in immune
escape mechanisms [4]. Tumour-associated microglia/macrophages (TAMs), which can constitute up
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to 30–40% of the bulk tumour mass, outnumber by far infiltrating lymphocytes in these tumours [3].
This scarcity of lymphocytes in the tumour microenvironment contrasts with other tumour types,
e.g., melanoma or lung cancer, therefore classifying GBM as immunologically ‘cold tumours’. Whether
or not these tumours are intrinsically non-immunogenic or whether lymphocytes, including T cells,
are actively excluded, remains to be determined [5]. In this context, an extensive immunogenomic
analysis of more than 10,000 tumours comprising data from 33 diverse cancer types compiled by The
Cancer Genome Atlas (TCGA) allowed to identify six different immune subtypes: wound healing, IFN-γ
dominant, inflammatory, lymphocyte depleted, immunologically quiet and TGF-β dominant [6]. Their
characterization was based on differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio,
extent of intra-tumour heterogeneity, aneuploidy, extent of neoantigen load, overall cell proliferation,
expression of immunomodulatory genes and prognosis. Notably, specific driver mutations correlated
with lower (CTNNB1, NRAS, or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte levels across all
cancers. Future studies should investigate the link between specific genomic alterations and their
contribution to the adaptation of the tumour microenvironment. As expected, in this classification
GBMs were among the “lymphocyte depleted” subtype displaying a prominent macrophage signature,
with Th1 suppressed and high M2 response [6].
Due to their large number in the tumour microenvironment, TAMs represent a key target for
GBM immunotherapy and a range of immunomodulatory agents are currently being trialled in
patients. For example, as TAMs critically depend on colony-stimulating factor-1 (CSF-1) for their
survival, differentiation and proliferation, strategies to target TAMs in the clinic include CSF-1 receptor
(CSF-1R) blockade [7,8]. However, despite having shown an effect on tumour growth in mouse
models, this approach failed to improve overall survival in patients [9], suggesting that putative TAM
subpopulations may be resistant to CSF-1R inhibition [10].
Despite extensive efforts in this direction, the precise role of TAMs in GBM onset and progression
as well as how TAMs may affect current immunotherapeutic approaches, including vaccines, oncolytic
viruses and immune-checkpoint inhibitors, remains unclear. Therefore, a deeper understanding of the
complexity and diversity of TAM adaptive features is critical to develop novel personalized immune
therapeutic strategies for GBM patients.
In this review, we will describe different features underlying TAMs heterogeneity and adaptation in
GBM. Further, we will pinpoint the aspects linked to their diversity that warrant further investigations
and how this heterogeneity may ultimately be harnessed for the development of novel personalized
immune therapeutic strategies.
2. Tumour-Associated Microglia/Macrophages in Glioblastoma
2.1. M1 and M2 Polarization States: The Basic School of Thought
Macrophages are highly dynamic cells whose molecular profiles are substantially influenced by
specific environmental cues. In vitro studies enabled classification of activated macrophages according
to a binary system, with pro-inflammatory cytokines (e.g., IFNγ) skewing them towards a classical
(M1-like) activation state, while anti-inflammatory cytokines (e.g., IL4) polarizing macrophages
into an alternative (M2-like) phenotype [11]. A similar dual classification has been described in
cultivated microglia exposed either to LPS/IFNγ or IL10/IL4 [12]. In cancer, this nomenclature has
been used for decades to discriminate M1-like anti-tumour versus M2-like pro-tumour macrophages,
with the latter assumed to constitute the majority of macrophages in the tumour according to their
immune-suppressive properties [13]. However, this simplistic classification described in vitro does not
apply to the in vivo situation as it only represents the two extremes of a continuum of activated states.
Over time, further intermediate states describing M2-like macrophages have been introduced, with a
putative M2c state associated to immune regulation, matrix deposition and tissue remodelling mostly
observed in brain malignancies [14]. However, despite these efforts, little exclusivity was observed
between these different categories of TAMs in GBM [15]. This is supported by studies conducted
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in GBM murine models where TAMs display an expression profile different from the predefined
M1 and M2 polarization states, including a mixture of M1- and M2-specific genes [16] or analyses
in GBM patients showing that TAMs exhibit a non-polarized M0 phenotype [17] (Figure 1). More
recently, another attempt to distinguish between pro- and anti-tumour macrophages has been based
on surface markers, where M1-like macrophages have been associated with the expression of CD40,
CD74, MHC-II and phosphorylated STAT1, whereas M2-like cells express CD163, CD204, arginase-1
(ARG1) and phosphorylated STAT3 [14]. However, these markers have also failed to provide a robust
separation and the subsequent understanding of their relative contribution to disease pathogenesis is
still unclear.
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Figure 1. Chronology of the characterization of tumour-associated microglia/macrophages (TAMs) 
heterogeneity in glioblastoma (GBM). Key studies that have contributed to elucidate TAMs 
polarization, ontogeny and subsets in GBM mouse models and patients. 
2.2. Impact of Ontogeny on Tumour-Associated Microglia/Macrophage Functionality 
The healthy brain harbours specific populations of tissue-resident macrophages effectively 
located in the parenchyma, perivascular spaces, meninges and choroid plexus where they maintain 
tissue homeostasis and ensure immune functions [18]. Within the parenchyma of the central nervous 
system (CNS), microglia are unique specialized immune effector cells that populate the brain early 
during embryogenesis [19]. In the adult brain, microglia continuously scan the environment and 
carry out several tasks, including neuronal support, phagocytosis of apoptotic cells and immune 
surveillance [20,21]. Their pool is maintained by self-renewal without contribution from bone 
marrow-derived progenitors, thus making microglia the only resident immune cell population in the 
healthy brain [22,23]. However, under certain pathological conditions, such as in GBM, the local 
inflammatory environment can compromise the integrity of the blood brain barrier leading to the 
infiltration of inflammatory monocytes from the circulation, which subsequently differentiate into 
monocyte-derived macrophages once they enter the brain tissue [24]. Therefore, in GBM, tumour-
associated macrophages encompass resident parenchymal microglia, perivascular macrophages and 
peripheral monocyte-derived cells [25]. As a general observation, although tumour-associated 
Fig re 1. ro olo of t e c aracterizatio of t o r-associate icro lia/ acro a es ( s)
eter e eit in glioblastoma (GBM). Key studies that have contributed to el ci ate TAMs polarization,
ontogeny a d subs ts in GBM mouse models and patients.
2.2. Impact of Ontogeny on Tumour-Associated icroglia/ acrophage Functionality
The healthy brain harbours specific populations of tissue-resident macrophages effectively located
in the parenchyma, perivascular spaces, meninges and choroid plexus where they maintain tissue
homeostasis and ensure immune functions [18]. Within the parenchyma of the central nervous
syste (CNS), icroglia are unique specialized i une effector cells that populate the brain early
during e bryogenesis [19]. In the adult brain, icroglia continuously scan the environ ent and
carry out several tasks, including neuronal support, phagocytosis of apoptotic cells and i une
surveillance [20,21]. Their pool is aintained by self-rene al ithout contribution fro bone
arro -derived progenitors, thus making microglia the only resident i mune cell population in
the healthy brain [22,23]. However, under certain pathological conditions, such as in GB , the local
infla atory environ ent can compromise the integrity of the blood brain barrier leading to
the infiltration of inflammatory monocytes from the circulation, which subsequently differentiate
into monocyte-derived macrophages once they enter the brain tissue [24]. Therefore, in GBM,
tumour-associated macrophages encompass resident parenchymal microglia, perivascular macrophages
and peripheral monocyte-derived cells [25]. As a general observation, although tu our-associated
macrophage proportions may vary in an organ-dependent manner, they have emerged as one of the
most critical cell types contributing to worse prognosis across the vast majority of cancers [26].
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In GBM, TAMs are recruited to the tumour site through various mediators, including CCL2,
CX3CL1, CSF-1, GM-CSF and osteopontin released by neoplastic cells [24,27–29]. Upon accumulation
at the tumour site, the functions of TAMs are supposed to be progressively overturned towards a
pro-tumorigenic phenotype. For example, TAMs promote immune suppression and angiogenesis
through the release of specific anti-inflammatory cytokines (e.g., TGFβ or IL10) and angiogenic factors
(e.g., VEGFα) (see reviews [14,30]. Functionally, microglia and monocyte-derived macrophages react
differently to various types of CNS insults [31] and the specific roles for these distinct cell populations
are now starting to emerge in GBM. For example, it has been recently shown that the immune
suppressive microenvironment in GBM patients depends on the accumulation of monocyte-derived
macrophages [32].
Experimentally, approaches to distinguish resident microglia from other inflammatory immune
cells entering the CNS have traditionally relied on CD45 expression to discriminate resident microglia
(CD11b+CD45low cells) from peripheral monocyte-derived macrophages (CD11b+CD45high cells) [33].
However, this strategy has been recently challenged showing that glioma-associated microglia
upregulate CD45 expression, thus limiting the effective discrimination of both populations in this
disease [34]. Recently, using multiple genetic lineage tracing in transgenic (GEMM-shP53) and syngeneic
GL261 mouse models, Bowman and collaborators have demonstrated that microglia specifically repress
Itga4 (CD49D), enabling the distinction between microglia and monocyte-derived macrophages in
murine tumours [35] (Figure 1). Gene expression profiling demonstrated that both populations exhibit
distinct activation states despite common traits of tumour education [35]. An unbiased meta-analysis
of five published murine transcriptional datasets identified discriminatory marker sets distinguishing
microglia versus peripheral monocytes/macrophages in health and gliomas [36]. These findings were
validated at the protein level using syngeneic GL261 and RCAS-PDGFB driven GBM mouse models,
where microglia-enriched genes included P2ry12, Tmem119, Slc2a5 and Fcrls, whereas Emilin2, Gda, Hp
and Sell were mainly expressed by peripheral monocytes/macrophages [36].
Further investigations will be critical to study how monocyte-derived macrophages in GBM
influence the immunological functions of resident microglia. For example, during CNS injuries,
peripheral macrophages affect nuclear factor kappa B (NFκB) signalling pathways in microglia
reducing their phagocytic and inflammatory responses [37]. In cancer, targeting NFκB prompts TAMs
towards a more cytotoxic anti-tumorigenic phenotype with a more activated state characterized by
higher IL12 and MHC-II expression together with reduced levels of IL10 and ARG1 [38].
3. Tumour-Associated Microglia/Macrophages as Therapeutic Targets in Glioblastoma
3.1. Effect of Chemotherapy and Radiotherapy on Tumour-Associated Microglia/Macrophages
To date, the combination of radio-chemotherapy with immunotherapeutic agents has not been
effective in GBM and drugs driving anti-tumour immune responses are currently evaluated in clinical
trials. In principle, radiation can increase in situ immunogenicity of malignant cells, thus improving
tumour immune recognition and T-cell mediated anti-tumour responses [39]. In these regimens,
it remains to be determined what is the optimal radiation dose and schedule to harness the best
immune effect. Moreover, it has to be considered that systemic administration of chemotherapeutic
agents has immunosuppressive effects, thus representing a major challenge for effective anti-cancer
immunotherapy-based strategies. In addition, high doses of glucocorticoids, such as dexamethasone,
are usually administered to GBM patients to reduce inflammation and radiotherapy-induced cerebral
oedema [40], thus dampening the inflammatory response by exerting profound effects on T cell subsets
and NK cells [41]. Regarding TAMs, they are supposed to have a bimodal response to chemotherapy
and radiotherapy, which can either reduce or amplify the magnitude of the anti-tumour responses [15].
These can be induced upon irradiation where targeted cancer cells generate damage-associated
molecular patterns (DAMPs), such as high mobility group box 1 (HMGB1), that are recognized by
pattern-recognition receptors (PRRs), including TLR2 and TLR4 in myeloid cells, that in turn trigger a
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pro-inflammatory phenotype [42]. Another route how radiation can induce anti-tumour immunity
in immunogenic tumours is via STING and type I IFN-dependent signalling in dendritic cells [43].
It remains to be seen whether such mechanisms are active in immunologically ‘cold tumours’ such as
GBM. Overall, it is evident that a thorough understanding of the complex interplay between tumour
immunogenicity, the immune system and the adjuvant therapy will be critical to optimize and fine-tune
the efficacy of immunotherapeutic approaches in GBM.
3.2. Depletion of Tumour-Associated Microglia/Macrophages in Glioblastoma
Upon accumulation to the tumour site, TAMs are thought to drive immune-suppression and
promote tumour progression. Due to their high numbers in GBM, their genomic stability and
adaptability to the microenvironment, several strategies to deplete TAMs have been developed.
For example, liposome-encapsulated clodronate, which has been commonly used to deplete macrophage
populations by inducing their apoptosis once phagocytosed by the cells, reduced tumour invasion
in GL261 cultured brain slices, which was restored after addition of TAMs [44]. However, it has
been recently demonstrated that intracerebral administration of clodronate liposomes into brain
parenchyma can deplete microglia, but can also damage other brain cells and blood vessel integrity [45],
therefore lacking specificity for TAMs. Further, attempts to specifically target peripheral macrophages,
for example limiting monocyte infiltration via Ccl2 genetic ablation, prolonged the survival of
tumour-bearing mice [46], but these approaches have not been applied to patients yet. On the
contrary, administration of ganciclovir to transgenic mice expressing thymidine kinase under the
CD11b promoter reduced the CD11b+ population and contributed to 30% of tumour increase in the
GBM syngeneic GL261 mouse model [47]. A major drawback of these studies is that these results were
obtained in highly immunogenic GBM mouse models, while GBMs in patients are poorly immunogenic
and display low T cell infiltration [48]. Further, TAMs depletion occurred prior to glioma cells
implantation, therefore gliomagenesis may be substantially affected in the absence of TAMs. In silico
studies have shown that TAM depletion therapy may be beneficial only for patients treated at early
stages with a concomitant cytokine therapy [49].
These results highlight that depleting TAMs indiscriminately is probably not the optimal approach,
as TAMs might play different roles depending on GBM features, including immunogenicity.
3.3. Immune Checkpoint Inhibitors and Reprogramming of Tumour-Associated Microglia/Macrophages
in Glioblastoma
Immunotherapy is emerging as a promising approach holding great potential to foster tumour
elimination by unleashing the immune system. The intense crosstalk between tumour cells, antigen
presenting cells (APCs) and T cells is intricately controlled by multiple ligand-receptor interactions,
known as checkpoints, which generally inhibit T-cell activation, ultimately affecting T cell cytotoxicity
against tumour cells [50]. For example, the binding of PD-L1 expressed by tumour cells to its receptor
PD-1 on T cells keeps the immune response in check. Hence, blocking this binding with an immune
checkpoint inhibitor (e.g., anti-PD-L1 or anti-PD-1) enables T cells to attack the tumour cells. Similarly,
the binding of APC-derived CD80/CD86 to CTLA-4 on T cells maintains the T cells in an inactive
state and interfering with this binding allows T cells to be reactive. Evidently, the efficacy of T
cell-based therapies is based on the amounts of tumour infiltrating lymphocytes (TILs), which are
remarkably low in GBM [51]. Preclinical studies in the immunogenic GL261 syngeneic GBM mouse
model have demonstrated the efficacy of targeting T cell immune-checkpoints, including CTLA-4, PD-1,
PD-L1 and PD-L2 as monotherapies or in combination with radiotherapy [52]. However, as indicated
above, this model poorly reflects human disease, since GBM patients typically show low mutational
load and weak tumour immunogenicity, which correlates with poor response to immune checkpoint
inhibitors [53]. The anti-PD-1 antibody advanced furthest in patients with GBM, however, in the phase
III clinical trial, despite showing drug safety, it did not meet the primary endpoint of the study [5].
Int. J. Mol. Sci. 2020, 21, 689 6 of 13
Due to TAMs abundance within GBM and their fast response to external stimuli, strategies to
re-educate TAMs in mouse glioma models may be more efficient than their depletion or the use of
immune checkpoint inhibitors. In this context, a promising target is signal-regulatory protein (SIRP) α,
an inhibitory receptor expressed on myeloid cells that recognizes the CD47 ligand on tumour cells
and contributes to immune evasion. The targeting of this axis with humanized anti-CD47 antibodies
enhanced tumour phagocytosis and reduced tumour burden in patient-derived orthotopic xenografts
of paediatric brain tumours [54]. Interesting results were also obtained using orthotopic xenografts
and a syngeneic mouse model with genetically color-coded macrophages (Ccr2RFP) and microglia
(Cx3cr1GFP), in which microglia were found to effectively phagocytose tumour cells in response to
anti-CD47 blockade with a reduced inflammatory signature, making them a promising target for
clinical applications [55]. Another example highlighting TAM subset-specific facets is the response
to the VEGF neutralizing antibody bevacizumab, where blood-derived TAMs, instead of resident
microglia, preferentially contributed to therapy resistance [56].
Combinatorial approaches targeting immune-suppressive populations concomitantly with
promoting endogenous anti-tumour immune responses successfully impaired tumour progression in
various subcutaneous tumour models. For example, dual targeting of suppressive myeloid populations
by inhibiting CSF-1/CSF-1R signalling and activation of APCs with CD40 agonists conferred superior
anti-tumour efficacy and increased survival compared with monotherapy. This effect was attributed to
the decrease of immunosuppressive TAMs and Foxp3+ regulatory T cells as well as accumulation of
tumour-infiltrating effector T cells exhibiting anti-tumorigenic features [57]. Further, the combination
of an oncolytic virus expressing IL-12 together with the two immune checkpoint inhibitors anti-CTLA-4
and anti-PD1 was able to significantly reduce tumour growth in GBM intracranial mouse models [58].
Lastly, monotherapies or combinatorial approaches targeting TAMs are currently being undertaken in
GBM clinical trials (Table 1).
Table 1. Examples of current clinical trials targeting TAMs in GBM. RT: radiotherapy; TMZ:
temozolomide; MRI: magnetic resonance imaging; LITT: laser interstitial thermal therapy; rGBM:
relapsed/recurrent glioblastoma.
Myeloid Target Drug Name Additional Treatment Study Phase Tumour Type Study Identifier
CSF-1R inhibitor Cabiralizumab Nivolumab (anti-PD-1) I GBM NCT02526017
CSF-1R inhibitor BLZ945 PDR001 (anti-PD-1) I/II GBM/rGBM NCT02829723
CSF-1R inhibitor Pexidartinib RT + TMZ I/II GBM NCT01790503
CXCR4 inhibitor USL311 Lomustine II rGBM NCT02765165
PD-L1 inhibitor Avelumab MRI-guided LITTtherapy I rGBM NCT03341806
STAT3 inhibitor WP1066 - I rGBM NCT01904123
GM-CSF VBI-1901 - I/II rGBM NCT03382977
MIF inhibitor Ibudilast TMZ I/II GBM/rGBM NCT03782415
Taken together, strategies aiming at reprogramming immunosuppressive myeloid cell populations
and/or fostering anti-tumour immune responses in the tumour microenvironment may be necessary
to empower checkpoint-based immune therapeutics in GBM. However, TAMs heterogeneity may
represent a barrier to non-selective immunotherapies, which seek to target TAMs indiscriminately.
4. Dissecting Tumour-Associated Microglia/Macrophages Diversity at Single-Cell Resolution
4.1. Glioblastoma Subtyping and Single-Cell Analyses
In the last 10 years, multiple attempts have used transcriptional profiling to sub-classify GBMs
into clinically meaningful tumour subtypes [59–61]. Although three common molecular subtypes
(mesenchymal, classical and proneural) have been proposed in various studies, they poorly correlate
with clinically relevant parameters, such as patient survival, except in a subgroup of patients [62].
Of note, the mesenchymal subtype was found to be characterized by a low tumour purity score along
with an enrichment of TAMs, highlighting the contribution of the microenvironment in transcriptional
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profiling based on bulk tissue analysis. Furthermore, surgical multisampling has revealed that
molecular subtypes can be present within the same patient tumour, suggesting that they do not
represent bonafide subtypes, but rather reflect heterogeneous cellular expression programs [63].
More recently, this has been confirmed by single-cell RNA-sequencing (scRNA-seq) revealing the
dynamic plasticity of GBM cells [64,65]. Hence, these studies highlight that tumour cells from a
distinct GBM biopsy can display molecular traits reflecting different cellular states, a concept that
is reminiscent of the M1 and M2 states in TAMs. Thus, at present the most promising classification
strategies for gliomas are based on DNA methylation, allowing to discriminate IDH-mutant gliomas
and IDH-wildtype gliomas [61,66].
4.2. Single-Cell Analyses of Microglia and Macrophages in Glioblastoma: Heterogeneity beyond Polarization
States and Ontogeny?
Recent scRNA-seq studies also highlighted tissue-specific myeloid cell heterogeneity associated
with distinct brain region-dependent transcriptional identities in health and disease [18,67,68].
For example, a specific disease-associated microglia subset localized around beta amyloid plaques
has been described in Alzheimer’s disease [69]. The existence of distinct subpopulations of microglia,
recently described under acute inflammatory conditions [70], suggests that different pools of microglia
readjust their phenotype in response to environmental stimuli. Supporting this concept, studies
conducted in neuroinflammatory diseases, including multiple sclerosis, have revealed the intricate
heterogeneity of the myeloid compartment of the central nervous system along disease progression [71].
Likewise, the heterogeneity of TAMs in GBM is also starting to emerge. For example, scRNA-seq
analyses of GBM biopsies demonstrated that TAMs frequently co-express canonical pro-inflammatory
(M1) and alternatively activated (M2) genes in individual cells [72] (Figure 1). Further, in low grade
gliomas, a gene signature of blood monocyte-derived TAMs, but not that of resident microglial TAMs,
correlated with poor survival [72]. Similar studies provided insights about the spatial localization of
TAMs. Correlation studies from a panel of established macrophage- and microglia-specific marker
genes [73] enabled identification of a macrophage core signature highly present within the tumour
core, while cells from the periphery expressed an evident microglia signature [74]. Additionally,
pro-inflammatory markers (e.g., IL1α and IL1β) were highly expressed at the tumour periphery, while
a more anti-inflammatory phenotype (e.g., IL1RN) was observed in the tumour core (Figure 2). Lastly,
subpopulations within the tumour core seemed to promote vascular permeability and endothelial
growth via the expression of VEGFα and an extracellular matrix remodelling gene signature [74].
The cellular composition of IDH-mutant gliomas was also unveiled by scRNA-seq, suggesting that
astrocytomas (IDH-A) and oligodendrogliomas (IDH-O) share common lineages of glial differentiation
with distinct tumour microenvironment signatures [75]. Specifically, a higher fraction of undifferentiated
and cycling tumour cells was associated with enriched microglia/macrophage signatures in IDH-A,
which correlated with tumour grade, thus providing a molecular fingerprint of tumour progression [76].
The authors propose that the composition of the tumour microenvironment may be driven by genetic
influences, such as TP53, which is mutated in IDH-A, but not IDH-O gliomas, and TP53 has been
shown to influence several immune pathways, including NF-kB [77].
In IDH-wildtype gliomas, it has been very recently shown that TAMs acquire a disease-associated
signature related to aging microglia programs, including downregulation of the microglia homeostatic
genes and upregulation of inflammatory, metabolic and interferon-associated genes. Various TAM
clusters, including subsets enriched for positive regulation of vasculature development or antigen
processing via MHC class I, have been identified [78] (Figure 1). Taken together, TAMs heterogeneity in
glioma is currently emerging and should be taken into account when designing therapeutic approaches
based on specific GBM features.
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avenues for novel combinatorial immunotherapies iming at restoring an efficient immune response
ult mately supporting the eradic ion of GBM.
Int. J. Mol. Sci. 2020, 21, 689 9 of 13
Author Contributions: Manuscript design and writing, Y.P.-A. and A.M.; Picture conception and creation, Y.P.-A.
and A.M.; Manuscript writing and editing, S.P.N.; Critical revision and approval of the final version of the
manuscript, S.P.N. and A.M. All authors have read and agreed to the published version of the manuscript.
Funding: Y.P.-A. was supported by the CANBIO Program of the Luxembourg National Research Fund
(PRIDE15/10675146/CANBIO) and by the Fondation du Pélican de Mie et Pierre Hippert-Faber (Fondation
de Luxembourg). We acknowledge financial support by the Luxembourg Institute of Health and the Luxembourg
Centre for Systems Biomedicine (MIGLISYS).
Conflicts of Interest: The authors declare no competing interests.
References
1. Goodenberger, M.L.; Jenkins, R.B. Genetics of adult glioma. Cancer Genet. 2012, 205, 613–621. [CrossRef]
2. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef]
3. Quail, D.F.; Joyce, J.A. The Microenvironmental Landscape of Brain Tumors. Cancer Cell 2017, 31, 326–341.
[CrossRef] [PubMed]
4. Glass, R.; Synowitz, M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol.
2014, 128, 347–362. [CrossRef] [PubMed]
5. Lim, M.; Xia, Y.; Bettegowda, C.; Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev.
Clin. Oncol. 2018, 15, 422–442. [CrossRef] [PubMed]
6. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.;
Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity 2018, 48, 812–830.e14. [CrossRef]
[PubMed]
7. Coniglio, S.J.; Eugenin, E.; Dobrenis, K.; Stanley, E.R.; West, B.L.; Symons, M.H.; Segall, J.E. Microglial
stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony
stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 2012, 18, 519–527. [CrossRef] [PubMed]
8. Patel, S.; Player, M.R. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and
inflammatory disease. Curr. Top. Med. Chem. 2009, 9, 599–610. [CrossRef] [PubMed]
9. Pyonteck, S.M.; Akkari, L.; Schuhmacher, A.J.; Bowman, R.L.; Sevenich, L.; Quail, D.F.; Olson, O.C.;
Quick, M.L.; Huse, J.T.; Teijeiro, V.; et al. CSF-1R inhibition alters macrophage polarization and blocks glioma
progression. Nat. Med. 2013, 19, 1264–1272. [CrossRef]
10. Quail, D.F.; Joyce, J.A. Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted
Therapies. Clin. Cancer Res. 2017, 23, 876–884. [CrossRef]
11. Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. Pillars Article: M-1/M-2 Macrophages and the
Th1/Th2 Paradigm. J. Immunol. 2017, 164, 6166–6173; Erratum in 2017, 199, 2194–2201. [CrossRef] [PubMed]
12. Michelucci, A.; Heurtaux, T.; Grandbarbe, L.; Morga, E.; Heuschling, P. Characterization of the microglial
phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and
fibrillar amyloid-beta. J. Neuroimmunol. 2009, 210, 3–12. [CrossRef]
13. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumor-associated
macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555.
[CrossRef]
14. Roesch, S.; Rapp, C.; Dettling, S.; Herold-Mende, C. When Immune Cells Turn Bad-Tumor-Associated
Microglia/Macrophages in Glioma. Int. J. Mol. Sci. 2018, 19, 436. [CrossRef]
15. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as treatment
targets in oncology. Nat. Rev. Clin. Oncol. 2017, 14, 399–416. [CrossRef] [PubMed]
16. Szulzewsky, F.; Pelz, A.; Feng, X.; Synowitz, M.; Markovic, D.; Langmann, T.; Holtman, I.R.; Wang, X.;
Eggen, B.J.; Boddeke, H.W.; et al. Glioma-associated microglia/macrophages display an expression profile
different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS ONE 2015, 10, e0116644.
[CrossRef] [PubMed]
17. Gabrusiewicz, K.; Rodriguez, B.; Wei, J.; Hashimoto, Y.; Healy, L.M.; Maiti, S.N.; Thomas, G.; Zhou, S.;
Wang, Q.; Elakkad, A.; et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage
phenotype. JCI Insight 2016, 1, e85841. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 689 10 of 13
18. Goldmann, T.; Wieghofer, P.; Jordao, M.J.; Prutek, F.; Hagemeyer, N.; Frenzel, K.; Amann, L.; Staszewski, O.;
Kierdorf, K.; Krueger, M.; et al. Origin, fate and dynamics of macrophages at central nervous system
interfaces. Nat. Immunol. 2016, 17, 797–805. [CrossRef]
19. Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Mehler, M.F.; Conway, S.J.; Ng, L.G.;
Stanley, E.R.; et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages.
Science 2010, 330, 841–845. [CrossRef]
20. Colonna, M.; Butovsky, O. Microglia Function in the Central Nervous System During Health and
Neurodegeneration. Annu. Rev. Immunol. 2017, 35, 441–468. [CrossRef]
21. Salter, M.W.; Stevens, B. Microglia emerge as central players in brain disease. Nat. Med. 2017, 23, 1018–1027.
[CrossRef] [PubMed]
22. Crotti, A.; Ransohoff, R.M. Microglial Physiology and Pathophysiology: Insights from Genome-wide
Transcriptional Profiling. Immunity 2016, 44, 505–515. [CrossRef] [PubMed]
23. Sousa, C.; Biber, K.; Michelucci, A. Cellular and Molecular Characterization of Microglia: A Unique Immune
Cell Population. Front. Immunol. 2017, 8, 198. [CrossRef] [PubMed]
24. Hambardzumyan, D.; Gutmann, D.H.; Kettenmann, H. The role of microglia and macrophages in glioma
maintenance and progression. Nat. Neurosci. 2016, 19, 20–27. [CrossRef]
25. Ricard, C.; Tchoghandjian, A.; Luche, H.; Grenot, P.; Figarella-Branger, D.; Rougon, G.; Malissen, M.;
Debarbieux, F. Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice.
Sci. Rep. 2016, 6, 26381. [CrossRef]
26. Cassetta, L.; Pollard, J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov.
2018, 17, 887–904. [CrossRef]
27. Li, W.; Graeber, M.B. The molecular profile of microglia under the influence of glioma. Neuro-Oncol. 2012, 14,
958–978. [CrossRef]
28. Wei, J.; Marisetty, A.; Schrand, B.; Gabrusiewicz, K.; Hashimoto, Y.; Ott, M.; Grami, Z.; Kong, L.Y.; Ling, X.;
Caruso, H.; et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential
therapeutic target. J. Clin. Investig. 2019, 129, 137–149. [CrossRef]
29. Zhang, J.; Sarkar, S.; Cua, R.; Zhou, Y.; Hader, W.; Yong, V.W. A dialog between glioma and microglia that
promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 2012, 33, 312–319.
[CrossRef]
30. Graeber, M.B.; Scheithauer, B.W.; Kreutzberg, G.W. Microglia in brain tumors. Glia 2002, 40, 252–259.
[CrossRef]
31. London, A.; Cohen, M.; Schwartz, M. Microglia and monocyte-derived macrophages: Functionally distinct
populations that act in concert in CNS plasticity and repair. Front. Cell. Neurosci. 2013, 7, 34. [CrossRef]
32. Pinton, L.; Masetto, E.; Vettore, M.; Solito, S.; Magri, S.; D’Andolfi, M.; Del Bianco, P.; Lollo, G.; Benoit, J.P.;
Okada, H.; et al. The immune suppressive microenvironment of human gliomas depends on the accumulation
of bone marrow-derived macrophages in the center of the lesion. J. Immunother. Cancer 2019, 7, 58. [CrossRef]
[PubMed]
33. Sedgwick, J.D.; Schwender, S.; Imrich, H.; Dorries, R.; Butcher, G.W.; ter Meulen, V. Isolation and direct
characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl.
Acad. Sci. USA 1991, 88, 7438–7442. [CrossRef] [PubMed]
34. Muller, A.; Brandenburg, S.; Turkowski, K.; Muller, S.; Vajkoczy, P. Resident microglia, and not peripheral
macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer 2015, 137, 278–288.
[CrossRef]
35. Bowman, R.L.; Klemm, F.; Akkari, L.; Pyonteck, S.M.; Sevenich, L.; Quail, D.F.; Dhara, S.; Simpson, K.;
Gardner, E.E.; Iacobuzio-Donahue, C.A.; et al. Macrophage Ontogeny Underlies Differences in Tumor-Specific
Education in Brain Malignancies. Cell Rep. 2016, 17, 2445–2459. [CrossRef] [PubMed]
36. Haage, V.; Semtner, M.; Vidal, R.O.; Hernandez, D.P.; Pong, W.W.; Chen, Z.; Hambardzumyan, D.; Magrini, V.;
Ly, A.; Walker, J.; et al. Comprehensive gene expression meta-analysis identifies signature genes that distinguish
microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathol. Commun. 2019, 7,
20. [CrossRef]
37. Greenhalgh, A.D.; Zarruk, J.G.; Healy, L.M.; Baskar Jesudasan, S.J.; Jhelum, P.; Salmon, C.K.; Formanek, A.;
Russo, M.V.; Antel, J.P.; McGavern, D.B.; et al. Peripherally derived macrophages modulate microglial
function to reduce inflammation after CNS injury. PLoS Biol. 2018, 16, e2005264. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 689 11 of 13
38. Hagemann, T.; Lawrence, T.; McNeish, I.; Charles, K.A.; Kulbe, H.; Thompson, R.G.; Robinson, S.C.;
Balkwill, F.R. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008,
205, 1261–1268. [CrossRef]
39. Nesseler, J.P.; Schaue, D.; McBride, W.H.; Lee, M.H.; Kaprealian, T.; Niclou, S.P.; Nickers, P. Irradiation to
Improve the Response to Immunotherapeutic Agents in Glioblastomas. Adv. Radiat. Oncol. 2019, 4, 268–282.
[CrossRef]
40. Brown, N.F.; Carter, T.J.; Ottaviani, D.; Mulholland, P. Harnessing the immune system in glioblastoma.
Br. J. Cancer 2018, 119, 1171–1181. [CrossRef]
41. Olnes, M.J.; Kotliarov, Y.; Biancotto, A.; Cheung, F.; Chen, J.; Shi, R.; Zhou, H.; Wang, E.; Tsang, J.S.;
Nussenblatt, R.; et al. Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci.
Rep. 2016, 6, 23002. [CrossRef]
42. Kalbasi, A.; June, C.H.; Haas, N.; Vapiwala, N. Radiation and immunotherapy: A synergistic combination. J.
Clin. Investig. 2013, 123, 2756–2763. [CrossRef]
43. Deng, L.; Liang, H.; Xu, M.; Yang, X.; Burnette, B.; Arina, A.; Li, X.D.; Mauceri, H.; Beckett, M.; Darga, T.; et al.
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent
Antitumor Immunity in Immunogenic Tumors. Immunity 2014, 41, 843–852. [CrossRef]
44. Markovic, D.S.; Glass, R.; Synowitz, M.; Rooijen, N.; Kettenmann, H. Microglia stimulate the invasiveness of
glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 2005, 64, 754–762.
[CrossRef]
45. Han, X.; Li, Q.; Lan, X.; El-Mufti, L.; Ren, H.; Wang, J. Microglial Depletion with Clodronate Liposomes
Increases Proinflammatory Cytokine Levels, Induces Astrocyte Activation, and Damages Blood Vessel
Integrity. Mol. Neurobiol. 2019, 56, 6184–6196. [CrossRef]
46. Chen, Z.; Feng, X.; Herting, C.J.; Garcia, V.A.; Nie, K.; Pong, W.W.; Rasmussen, R.; Dwivedi, B.; Seby, S.;
Wolf, S.A.; et al. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.
Cancer Res. 2017, 77, 2266–2278. [CrossRef]
47. Galarneau, H.; Villeneuve, J.; Gowing, G.; Julien, J.P.; Vallieres, L. Increased glioma growth in mice depleted
of macrophages. Cancer Res. 2007, 67, 8874–8881. [CrossRef]
48. Alban, T.J.; Alvarado, A.G.; Sorensen, M.D.; Bayik, D.; Volovetz, J.; Serbinowski, E.; Mulkearns-Hubert, E.E.;
Sinyuk, M.; Hale, J.S.; Onzi, G.R.; et al. Global immune fingerprinting in glioblastoma patient peripheral
blood reveals immune-suppression signatures associated with prognosis. JCI Insight 2018, 3, e122264.
[CrossRef] [PubMed]
49. Wu, Y.; Lu, Y.; Chen, W.; Fu, J.; Fan, R. In silico experimentation of glioma microenvironment development
and anti-tumor therapy. PLoS Comput. Biol. 2012, 8, e1002355. [CrossRef] [PubMed]
50. Boussiotis, V.A.; Charest, A. Immunotherapies for malignant glioma. Oncogene 2018, 37, 1121–1141. [CrossRef]
[PubMed]
51. Tomaszewski, W.; Sanchez-Perez, L.; Gajewski, T.F.; Sampson, J.H. Brain Tumor Microenvironment and Host
State: Implications for Immunotherapy. Clin. Cancer Res. 2019, 25, 4202–4210. [CrossRef] [PubMed]
52. Reardon, D.A.; Gokhale, P.C.; Klein, S.R.; Ligon, K.L.; Rodig, S.J.; Ramkissoon, S.H.; Jones, K.L.; Conway, A.S.;
Liao, X.; Zhou, J.; et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic,
Immunocompetent Model. Cancer Immunol. Res. 2016, 4, 124–135. [CrossRef] [PubMed]
53. Yarchoan, M.; Hopkins, A.; Jaffee, E.M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
N. Engl. J. Med. 2017, 377, 2500–2501. [CrossRef] [PubMed]
54. Gholamin, S.; Mitra, S.S.; Feroze, A.H.; Liu, J.; Kahn, S.A.; Zhang, M.; Esparza, R.; Richard, C.; Ramaswamy, V.;
Remke, M.; et al. Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is
an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med. 2017, 9, eaaf2968. [CrossRef]
55. Hutter, G.; Theruvath, J.; Graef, C.M.; Zhang, M.; Schoen, M.K.; Manz, E.M.; Bennett, M.L.; Olson, A.;
Azad, T.D.; Sinha, R.; et al. Microglia are effector cells of CD47-SIRPalpha antiphagocytic axis disruption
against glioblastoma. Proc. Natl. Acad. Sci. USA 2019, 116, 997–1006. [CrossRef]
56. Castro, B.A.; Flanigan, P.; Jahangiri, A.; Hoffman, D.; Chen, W.; Kuang, R.; De Lay, M.; Yagnik, G.; Wagner, J.R.;
Mascharak, S.; et al. Macrophage migration inhibitory factor downregulation: A novel mechanism of
resistance to anti-angiogenic therapy. Oncogene 2017, 36, 3749–3759. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 689 12 of 13
57. Wiehagen, K.R.; Girgis, N.M.; Yamada, D.H.; Smith, A.A.; Chan, S.R.; Grewal, I.S.; Quigley, M.; Verona, R.I.
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and
Drives Potent Antitumor Immunity. Cancer Immunol. Res. 2017, 5, 1109–1121. [CrossRef]
58. Saha, D.; Martuza, R.L.; Rabkin, S.D. Macrophage Polarization Contributes to Glioblastoma Eradication
by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell 2017, 32, 253–267.e5.
[CrossRef]
59. Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.;
Colman, H.; Soroceanu, L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157–173. [CrossRef]
60. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.;
Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [CrossRef]
61. Ceccarelli, M.; Barthel, F.P.; Malta, T.M.; Sabedot, T.S.; Salama, S.R.; Murray, B.A.; Morozova, O.; Newton, Y.;
Radenbaugh, A.; Pagnotta, S.M.; et al. Molecular Profiling Reveals Biologically Discrete Subsets and
Pathways of Progression in Diffuse Glioma. Cell 2016, 164, 550–563. [CrossRef] [PubMed]
62. Wang, Q.; Hu, B.; Hu, X.; Kim, H.; Squatrito, M.; Scarpace, L.; de Carvalho, A.C.; Lyu, S.; Li, P.; Li, Y.; et al.
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in
the Microenvironment. Cancer Cell 2017, 32, 42–56.e6. [CrossRef] [PubMed]
63. Sottoriva, A.; Spiteri, I.; Piccirillo, S.G.; Touloumis, A.; Collins, V.P.; Marioni, J.C.; Curtis, C.; Watts, C.;
Tavare, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl.
Acad. Sci. USA 2013, 110, 4009–4014. [CrossRef] [PubMed]
64. Neftel, C.; Laffy, J.; Filbin, M.G.; Hara, T.; Shore, M.E.; Rahme, G.J.; Richman, A.R.; Silverbush, D.; Shaw, M.L.;
Hebert, C.M.; et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell
2019, 178, 835–849.e21. [CrossRef] [PubMed]
65. Patel, A.P.; Tirosh, I.; Trombetta, J.J.; Shalek, A.K.; Gillespie, S.M.; Wakimoto, H.; Cahill, D.P.; Nahed, B.V.;
Curry, W.T.; Martuza, R.L.; et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary
glioblastoma. Science 2014, 344, 1396–1401. [CrossRef] [PubMed]
66. Capper, D.; Jones, D.T.W.; Sill, M.; Hovestadt, V.; Schrimpf, D.; Sturm, D.; Koelsche, C.; Sahm, F.; Chavez, L.;
Reuss, D.E.; et al. DNA methylation-based classification of central nervous system tumours. Nature 2018,
555, 469–474. [CrossRef]
67. Van Hove, H.; Martens, L.; Scheyltjens, I.; De Vlaminck, K.; Pombo Antunes, A.R.; De Prijck, S.; Vandamme, N.;
De Schepper, S.; Van Isterdael, G.; Scott, C.L.; et al. A single-cell atlas of mouse brain macrophages reveals
unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 2019, 22,
1021–1035. [CrossRef]
68. Mrdjen, D.; Pavlovic, A.; Hartmann, F.J.; Schreiner, B.; Utz, S.G.; Leung, B.P.; Lelios, I.; Heppner, F.L.; Kipnis, J.;
Merkler, D.; et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals
Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 2018, 48, 380–395.e6. [CrossRef]
69. Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.;
Baruch, K.; Lara-Astaiso, D.; Toth, B.; et al. A Unique Microglia Type Associated with Restricting Development
of Alzheimer’s Disease. Cell 2017, 169, 1276–1290.e17. [CrossRef]
70. Sousa, C.; Golebiewska, A.; Poovathingal, S.K.; Kaoma, T.; Pires-Afonso, Y.; Martina, S.; Coowar, D.; Azuaje, F.;
Skupin, A.; Balling, R.; et al. Single-cell transcriptomics reveals distinct inflammation-induced microglia
signatures. EMBO Rep. 2018, 19, e46171. [CrossRef]
71. Jordao, M.J.C.; Sankowski, R.; Brendecke, S.M.; Locatelli, G.; Tai, Y.H.; Tay, T.L.; Schramm, E.; Armbruster, S.;
Hagemeyer, N.; Gross, O.; et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during
neuroinflammation. Science 2019, 363, eaat7554. [CrossRef] [PubMed]
72. Muller, S.; Kohanbash, G.; Liu, S.J.; Alvarado, B.; Carrera, D.; Bhaduri, A.; Watchmaker, P.B.; Yagnik, G.;
Di Lullo, E.; Malatesta, M.; et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a
basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017,
18, 234. [CrossRef] [PubMed]
73. Bennett, M.L.; Bennett, F.C.; Liddelow, S.A.; Ajami, B.; Zamanian, J.L.; Fernhoff, N.B.; Mulinyawe, S.B.;
Bohlen, C.J.; Adil, A.; Tucker, A.; et al. New tools for studying microglia in the mouse and human CNS.
Proc. Natl. Acad. Sci. USA 2016, 113, E1738–E1746. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 689 13 of 13
74. Darmanis, S.; Sloan, S.A.; Croote, D.; Mignardi, M.; Chernikova, S.; Samghababi, P.; Zhang, Y.; Neff, N.;
Kowarsky, M.; Caneda, C.; et al. Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the
Migrating Front of Human Glioblastoma. Cell Rep. 2017, 21, 1399–1410. [CrossRef] [PubMed]
75. Lucas, C.G.; Solomon, D.A.; Perry, A. A review of recently described genetic alterations in central nervous
system tumors. Hum. Pathol. 2019. [CrossRef]
76. Venteicher, A.S.; Tirosh, I.; Hebert, C.; Yizhak, K.; Neftel, C.; Filbin, M.G.; Hovestadt, V.; Escalante, L.E.;
Shaw, M.L.; Rodman, C.; et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas
by single-cell RNA-seq. Science 2017, 355, eaai8478. [CrossRef]
77. Munoz-Fontela, C.; Mandinova, A.; Aaronson, S.A.; Lee, S.W. Emerging roles of p53 and other
tumour-suppressor genes in immune regulation. Nat. Rev. Immunol. 2016, 16, 741–750. [CrossRef]
78. Sankowski, R.; Bottcher, C.; Masuda, T.; Geirsdottir, L.; Sagar; Sindram, E.; Seredenina, T.; Muhs, A.;
Scheiwe, C.; Shah, M.J.; et al. Mapping microglia states in the human brain through the integration of
high-dimensional techniques. Nat. Neurosci. 2019, 22, 2098–2110. [CrossRef]
79. Kumar, M.P.; Du, J.; Lagoudas, G.; Jiao, Y.; Sawyer, A.; Drummond, D.C.; Lauffenburger, D.A.; Raue, A.
Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics.
Cell Rep. 2018, 25, 1458–1468.e4. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
